Sirgartan Therapeutics is an early-stage drug development company established in 2020 with the vision to transform the treatment paradigm for OCD (obsessive compulsive disorder) and deliver life-changing medicines for patients with OCD and other related neuropsychiatric disorders. The company’s mission is to identify and develop innovative single or combination treatments for OCD in conjunction with the world-leading neurological research resource provided by the University of Cambridge, UK..
Show MoreSirgartan Therapeutics is an early-stage drug development company established in 2020 with the vision to transform the treatment paradigm for OCD (obsessive compulsive disorder) and deliver life-changing medicines for patients with OCD and other related neuropsychiatric disorders. The company’s mission is to identify and develop innovative single or combination treatments for OCD in conjunction with the world-leading neurological research resource provided by the University of Cambridge, UK.
Sirgartan is also investigating other potential neurological disorder therapies in conjunction with the Cambridge Consulting Network (CCN). These will constitute the pipeline for further studies into mental illnesses, including eating disorders, body dysmorphia and a range of other less recognised, but highly debilitating conditions.
Investment obtained through initial seed-funding has enabled early- stage pre-clinical studies to be carried out by the University of Cambridge. These studies have shown very encouraging results, much to the satisfaction of Professor Trevor Robbins, Chief Scientific Advisor to Sirgartan. This has led to the recent submission of a patent application for the identified therapy and its method of action.
The organisation is now seeking further funding to enable progression into clinical studies in 2023. Please contact us at investors@sigartan.com should you or your organisation have an interest in investing in this opportunity..
Professor Robbins works in neuropsychopharmacology and behavioural and cognitive neuroscience. He has strong interests in drug discovery, having consulted for most of the major pharmaceutical companies, and in translational research. As Director of the MRC and Wellcome Trust, he co-funded the Behavioural and Clinical Neuroscience Institute (BCNI).
David Cavalla has 35 years’ experience in various senior scientific and commercial roles within the pharmaceutical industry. He is currently involved with a number of biotech companies at Board level.
Dr Anthony Hall is Chief Medical Officer at Sirgartan Therapeutics. He graduated from King’s College London with first class joint honours in physiology and pharmacology before going on to study medicine at the Royal Free Hospital. He has over 25 years of drug development with ten years working on rare diseases.
Christa van Kan has more than 25 years of experience in managing clinical trials in a broad range of diseases, including many orphan and paediatric indications. She was one of the co-founders and owners of PSR Orphan Experts, a niche CRO. As Director of Clinical Operations, she also acted as a hands-on Project Director, staying in close contact with all relevant stakeholders.
Jon E. Grant is a Professor of Psychiatry & Behavioral Neuroscience at the University of Chicago where he directs a clinic and research lab on addictive, compulsive and impulsive disorders.
With over 20 years of experience as a finance professional, Julia’s areas of expertise include software implementation and accounting processes, working with notable pharmaceutical clients such as Healx, AMO Pharma and Ventus Medial Ltd.
Lisa Stone has a strong record as a financial and operational leader, with experiences spanning venture capital, private equity, life sciences and real estate.
Ekaterina received her medical degree from St Petersburg Medical Academy in St Petersburg, Russia, and then moved to the US where she completed her Internal Medicine residency training. She worked in private practice, academic medicine and public health for more than 15 years in the greater New York area.
a field which has historically been underfunded
and seen limited innovation.